Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad

Phase 4

Not yet recruiting

• Conditions: Malaria Infection; Malaria Vaccines

• Registration Number: NCT07038837
• Lead Sponsor: Epicentre

Brief Summary

This is a two-arm, cluster-randomised, phase IV trial conducted in Chad to assess the protective efficacy and impact in real-life conditions of a new strategy for administering the R21/MM malaria vaccine, synchronized within a seasonal malaria chemoprevention (SMC) campaign, among children living in areas of high seasonal malaria transmission.

In this study, a cluster is defined as the catchment area of a primary care health centre. In Chad, each catchment area is known as a 'zone of responsibility' (French: Zone de Responsibilité' \[ZR\]).

Twenty-six (26) of the total 27 ZRs in the districts of Moïssala and Dembo will be randomized in a 1:1 ratio to receive a 4-dose (3 primary doses + 1 booster) R21/MM schedule either (1) integrated into the routine EPI vaccination program (the "Routine" control arm), or (2) synchronized with an annual seasonal malaria chemoprevention (SMC) campaign (the "Synchronized" intervention arm).

Malaria incidence: R21/MM effectiveness will be assessed using the incidence of biologically confirmed clinical malaria (trial primary endpoint). The incidence of clinical malaria will be determined through enhanced surveillance of malaria cases in health centres and hospitals over a 17-month period (August 2025 - December 2026).

Coverage surveys: Cross-sectional surveys (cluster sampling) will be carried out to measure R21/MM vaccine coverage, SMC coverage, coverage of other malaria prevention measures, and coverage of other EPI vaccines.

Nested case-control study: A sub-sample of children admitted to Moïssala District Hospital with severe clinical malaria will be offered the opportunity to participate in a nested case-control study designed to estimate the individual protective efficacy of R21/MM against severe malaria.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-06
• Study First Submitted: 2025-06-03
• Study First Submitted QC: 2025-06-17
• Last Update Submitted: 2025-06-17
• Study First Posted: 2025-06-26
• Last Update Posted: 2025-06-26
• Study Start: 2025-07-02
• Primary Completion: 2026-12
• Study Completion: 2028-06-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 70000

Inclusion Criteria

• • Routine arm

  1. Aged 6 to 11 months at the time of the first R21/MM vaccination (dose 1).

  2. Residing in a village participating in the study and randomized to the routine arm.

  3. Oral consent provided by the child's parent/guardian.

     • Synchronised arm
  <!-- -->
  1. Aged 6 to 59 months at the time of the first R21/MM vaccination (dose 1) during the first 3 rounds of SMC (2025).
  2. Residing in a village participating in the study and randomized to the synchronized arm.
  3. Oral consent provided by the child's parent/guardian.

Exclusion Criteria

• Exclusion criteria for both arms according to Chad national EPI guidelines

Malaria vaccine is not recommended for children with known severe hypersensitivity:

• To a previous dose of a malaria vaccine
• To a previous dose of hepatitis B vaccine
• One of the components of the R21/MM vaccine

Mild illness - including respiratory tract infections, mild diarrhoea and fever below 38.5° C - is not a contraindication to R21/MM vaccination. Malnutrition and being HIV-seropositive are also not contraindications to R21/MM vaccination.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Malaria incidence in children who were aged 6-11 months when receiving their first dose R21/MM	From enrollment to Month 17 (Aug 2025- december 2026)	To assess whether the R21/MM vaccine synchronized with SMC is non-inferior in preventing malaria (based on malaria incidence) compared to R21/MM administered as part of routine EPI in children who were aged 6-11 months when receiving their first dose R21

Secondary Outcome Measures

Name	Time	Method
Malaria incidence	from enrolment to Month 17 (Aug 2025- Dec 2026)	Incidence of clinical malaria (biologically confirmed by RDT) in each study arm among children aged 6-59 months, irrespective of R21/MM vaccination status
R21/MM vaccination coverage	from enrolment to Month 17 (Aug 2025- Dec 2026)	Proportion of children having received the appropriate number of doses for their age
Coverage of other malaria prevention measures	From enrolment to month 17 (Aug 2025- Dec 2026)	SMC coverage: average number of doses received per child and proportion of children receiving 0 and 5 doses
Coverage of other EPI antigens	from enrolment to Month 17 (Aug 2025- Dec 2026)	o Proportion of age-eligible children vaccinated against measles-1 and measles-2.
Protective efficacy against severe malaria	From enrollment to Month 17 (Aug 2025- december 2026)	Protective efficacy of vaccination with R21/MM will be measured at the individual level against severe malaria confirmed by RDT and microscopy. The protective efficacy will be calculated from the relative risk (RR) of developing severe malaria in vaccinated and unvaccinated children.
Proportional morbidity	From enrollment to Month 17 (Aug 2025- december 2026)	o Proportion of all-cause morbidity registered at health centres attributed to uncomplicated malaria
R21/MM safety	From enrollment to Month 17 (Aug 2025- december 2026)	o Frequency of reported serious adverse events (SAEs), adverse events following immunization (AEFI), Serious AEFIs and reported adverse events of special interest (AESIs) following R21/MM vaccination

Trial Locations

Locations (1)

Medecin sans Frontières; 🇹🇩 Moissala, Mandoul region, Chad